Cargando…
R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma
Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma. Despite the clinical benefit of propranolol therapy in hemangioma, the mechanistic understanding of what drives this outcome is limited. Here, we report successful treatment of pericard...
Autores principales: | Overman, Jeroen, Fontaine, Frank, Wylie-Sears, Jill, Moustaqil, Mehdi, Huang, Lan, Meurer, Marie, Chiang, Ivy Kim, Lesieur, Emmanuelle, Patel, Jatin, Zuegg, Johannes, Pasquier, Eddy, Sierecki, Emma, Gambin, Yann, Hamdan, Mohamed, Khosrotehrani, Kiarash, Andelfinger, Gregor, Bischoff, Joyce, Francois, Mathias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667216/ https://www.ncbi.nlm.nih.gov/pubmed/31358114 http://dx.doi.org/10.7554/eLife.43026 |
Ejemplares similares
-
Homodimerization regulates an endothelial specific signature of the SOX18 transcription factor
por: Moustaqil, Mehdi, et al.
Publicado: (2018) -
Non–beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma
por: Seebauer, Caroline T., et al.
Publicado: (2022) -
Functional domain analysis of SOX18 transcription factor using a single-chain variable fragment-based approach
por: Fontaine, Frank R., et al.
Publicado: (2018) -
Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice
por: Overman, Jeroen, et al.
Publicado: (2017) -
Correction: Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice
por: Overman, Jeroen, et al.
Publicado: (2023)